Stockpolly
Search
DMAC · NASDAQ · Biotechnology

DiaMedica Therapeutics (DMAC)

Develops DM199 for preeclampsia, fetal growth restriction, and acute ischemic stroke.

$6.89
Pre-market+0.13 (+1.92%)
At close$6.76(+4.81%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
56667888991010
Research & development344456666788
222222223322
General & administrative222222223322
Other expenses000000000000
Operating income−5−6−6−6−7−8−8−8−9−9−10−10
111111000000
Other non-operating income0−1−1−1−1−1000000
Income before tax−4−5−5−5−6−8−8−8−9−9−10−10
Income tax expense00000—000000
Net income from continuing operations−4−5−5−5−6−8−8−8−9−9−10−10
Other adjustments000000000000
Net income−4−5−5−5−6−8−8−8−9−9−10−10
EPS, basic−$0.12−$0.14−$0.14−$0.13−$0.15−$0.18−$0.18−$0.18−$0.17−$0.17−$0.19−$0.19
EPS, diluted−$0.12−$0.14−$0.14−$0.13−$0.15−$0.18−$0.18−$0.18−$0.17−$0.17−$0.19−$0.19
Weighted average shares, basic383838384343434350475454
Weighted average shares, diluted383838384343434350475454
EBITDA−5−5−5−5−6−8−8−8−9−9−10−10
Depreciation & amortization000000000000
EBIT−5−5−5−5−6−8−8−8−9−9−10−10